RA CAPITAL MANAGEMENT, L.P. purchased $413K of ARTV (indirect holdings)
RA CAPITAL MANAGEMENT, L.P. purchased 41,319 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at $9.99 ($0.41M total) on 2026-07-24.
How this was made
The 30-second read
Why it matters
The newest fact is the reported open-market purchase size, price, and post-transaction indirect holdings, which may slightly influence sentiment but does not change fundamentals in the text.
Market read
Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing without accompanying business updates.
What to watch
Indirect holdings and role-based reporting can obscure the true economic exposure and timing; traders should not treat this as a substitute for upcoming clinical or financial catalysts.
Background
The article is an SEC Form 4 insider transaction disclosure for Artiva Biotherapeutics, Inc. (ARTV).
Ticker impact
RA Capital Management, L.P. reported an open-market purchase of 41,319 shares of Artiva Biotherapeutics at $9.9900 on 2026-07-24.
Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.
This is a primary-source insider transaction disclosure with defined size and price, but it does not include new operating, clinical, or financial information that would re-rate the business.
Market effects
No direct sector read-across; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Insider buys under a 10b5-1 plan are often more informative; here the filing states no pre-arranged 10b5-1 plan, which can also mean the trade may be opportunistic rather than thesis-driven.
Key entities
- issuerArtiva Biotherapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insider_filerRA Capital Management, L.P.
Reported an open-market purchase as a director and 10% owner with indirect holdings.
